Byooviz is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Biogen Inc.. The primary component is Ranibizumab.
Product ID | 64406-019_1c0b50cf-e8c4-45ab-bbb0-4a241c25c062 |
NDC | 64406-019 |
Product Type | Human Prescription Drug |
Proprietary Name | Byooviz |
Generic Name | Ranibizumab-nuna |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVITREAL |
Marketing Start Date | 2022-06-01 |
Marketing Category | BLA / |
Application Number | BLA761202 |
Labeler Name | BIOGEN INC. |
Substance Name | RANIBIZUMAB |
Active Ingredient Strength | 10 mg/mL |
Pharm Classes | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2022-06-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
BYOOVIZ 90687009 not registered Live/Pending |
Biogen MA Inc. 2021-05-03 |
BYOOVIZ 90071392 not registered Live/Pending |
Biogen MA Inc. 2020-07-24 |